MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Kenichi Inoue et al.|Journal of Clinical Oncology|2017Cited by 1.7k
Comprehensive Characterization of Human Genome Variation by High Coverage Whole-Genome Sequencing of Forty Four CaucasiansHui Shen, Hong‐Wen Deng, Jian Li et al.|PLoS ONE|2013Cited by 81
Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibitionQiong Wang, Yong Lin|Oncotarget|2014Cited by 39
A Randomized Phase I Trial Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eclitasertib, a RIPK1 Inhibitor, in Healthy ParticipantsChristine Farenc, Yong Lin|Advances in Therapy|2025Cited by 1